Articles
Investigations, methods, and market analysis built from TitrateLab's COA, inventory, community, and regulatory evidence.
- Most popular
-
The $150,000 rugpull: Eric Ranks, 'Mr. Based,' and the Peptide University fake-vendor machine
The Peptide University group-buy "rugpull," explained: how "Mr. Based," Eric Ranks, and the vendors "Bella" and RX Anabolics took roughly $150,000 from members — with the crypto traced on-chain to Coinbase, Binance and OKX. The same grey-market playbook, run at least twice: stand up a vendor nobody can verify, vouch it into trust, funnel members' money, then blame the vendor.
-
ERP, WBS and JKL: Three Names, One Chinese Peptide Supplier?
Why do ERP, WBS and JKL look connected? Shared ads, codes and pricing point to one supply network and reputation insulation across three public names.
-
Retatrutide Purity Tests: What 12,209 Results Show
TitrateLab's retatrutide COA analysis covers 12,209 reported purity results: 96.0% were 99–100%, while 164 amount results measured 0 mg. See the limits.
-
Medicare Part D Spending on Ozempic and Mounjaro in 2024
Medicare Part D spending was $12.97B for Ozempic and $6.34B for Mounjaro in 2024, before rebates. Compare CMS ranks, Medicaid totals and evidence limits.
-
What Is a Domestic “10x” Peptide Reseller?
What a domestic “10x” peptide reseller does, how kit and single-vial prices compare, and how batch numbers can help you look past the label.
-
Top 5 International Retatrutide Sellers by Testing Volume
Compare five international retatrutide sellers across 677 lab reports: testing volume, recent coverage, identity failures and reliability limits.
-
The Hidden Risks of Ordering Peptides in Canada
A 100 mg peptide kit can exceed 90 days of trial supply. What Canada's import rules, package inspections and enforcement powers mean for buyers.
-
Janoshik and Vanguard Smack Down Chromate: Inside the Peptide Lab War—and Why the Same Batch Gets Different Results
Janoshik, Vanguard and Chromate clash over peptide testing methods. Our review found major conflicts in 123 of 179 matched batch-code groups.
-
The Worst Peptide Vendors in 2026, According to Independent Lab Tests
Five peptide vendors with the worst documented identity and underfill records in TitrateLab's current independent testing data.
-
How to Verify a Peptide COA—and Why a Valid Certificate May Not Prove Your Vial
Verify and read a peptide COA by checking the lab record, report number, batch, date and test scope. A valid report proves one submitted sample—not your vial.
-
A Study Said Up to 71% of Grey-Market Peptides Failed. We Checked 64,787 Lab Records.
A preprint reported a 41.6%–71.1% failure rate. TitrateLab reproduced the math, then separated wrong identity, low purity, underfill and overfill across 64,787 checkable lab records.
-
Peptaura promised a race to the bottom on price. What it delivered was a race to the bottom on quality.
Peptaura brands its own peptides, arranges their laboratory testing, publishes the certificates and marks them verified. Across 112 independent certificates for its flagship Lumira/Welon line, 20 came back as the wrong compound entirely. Newer records show both sides of its response: another identity failure in August, and a separate failed group test that Peptaura did recall.
-
QSC Tracy Review: Strong Lab Results, Serious Trust Problems
A data-driven review of QSC and its sales persona Tracy: strong independent lab results, review-linked pricing, customer disputes, and a MESO-Rx ban.
-
FDA scientists recommended against all seven peptides. The panel voting July 23 was rebuilt to say yes anyway.
On June 30, 2026, three weeks before the FDA Pharmacy Compounding Advisory Committee votes on seven peptides, the agency's own staff scientists recommended against all seven on insufficient-evidence grounds. The panel that votes July 23-24 was reconstituted with members who prescribe, produce, and promote peptides. A follow-up to our April preview, corrected against the record: the real agenda is 7 peptides (not 14), nothing is being "restored," the last peptide vote went 0-for-7, and our 22,762 lab reports answer a question the FDA is not asking.
-
Retatrutide Costs $0.78/mg at the Source. Resellers Charge You 3x to 22x for the Same Vial.
We priced six of the most-bought research peptides at the source, the per-mg number one hop below the US reseller layer, against the cheapest reseller (DisclosedLabs) and the vendor median (PeptideBase). Retatrutide runs $0.78/mg at the source and $10.00/mg at the reseller median, a 12.9x markup. Tirzepatide is 22.3x. We walk through the relabel supply chain that makes the same vial cost 3x to 22x more under a domestic brand, ask the two fair questions about price aggregators, and stay honest about the real grey-market risks, which is why we publish the COAs.
-
GLP-1s and Hair Loss: One Real Signal, One Shaky One, and the Users Who Never Show Up in the Data
A pharmacovigilance study of six GLP-1 drugs found hair loss reported 23 percent more often, and PCOS 6.6 times more often, for semaglutide in the FDA adverse-event database. We read the actual paper: why the hair-loss signal most likely tracks rapid weight loss, why the reproductive number is loud but probably confounded, why the study found the other GLP-1s quieter rather than identical, and why grey-market self-sourcers are invisible to the whole system.
-
Over-filled, or short-changed? What 15,167 COAs say about grey-market peptide dosing
Are grey-market peptides correctly dosed? We collected 22,588 certificates of analysis from independent labs and measured the 15,167 that report a dose against the label. The counterintuitive finding on grey-market peptide dose accuracy: most vials are over-filled, not short. Over-fills are common and shallow; under-fills are rarer but run deeper. The full per-compound breakdown, and why the independent-lab-only cut tells the honest story.
-
The Mystery Retatrutide Patient: One Person Got Early Access While Millions Wait
A single unnamed patient was granted early access to the unapproved weight-loss drug retatrutide through the FDA compassionate-use pathway. A coincidence of age set off speculation about who it was; the White House denied it. The plain-language version of what was reported, what is actually confirmed, and why the real story for grey-market buyers is the access gap.
-
Peptides for Aging Bones and Joints: What's Proven, What's Hype
Can peptides heal aging bones and joints? Every candidate mapped by evidence tier: bone-building is proven FDA medicine, while the joint, tendon, and cartilage claims are strong in animals but unproven in humans.
-
Pharma's Quality Bar Is Lower Than You Think. We Measured 62,079 Grey-Market Peptide Tests Against It.
"Pharmaceutical grade" is the grey market's favorite phrase. We read the rules pharma actually follows, the real USP and FDA limits, and they are looser than most buyers assume: a compliant drug can be 10% off its label, and 95% purity can pass for a peptide. Then we measured 62,079 grey-market peptide certificates against those exact bars. As of July 2026 the dose bar is met by a bare majority, 51.3%. The purity number is a decoy. The endotoxin gap is the one that should change how you buy.
-
Does DSIP Actually Work? An Honest Evidence Review
Does DSIP actually work? The honest evidence read: tiny old studies (n=6-16), the best-controlled trial weak-to-negative, no receptor or gene in 49 years, and no modern RCTs. Research-use-only.
-
XTP Sold a Retatrutide That Tested as Tirzepatide, Then Said No Test Ever Showed It
Between late May and July 2026, independent lab tests on products from XTP (known in channels as Xi'an Taiye Chemical Co.) found a multi-product quality collapse on batch XTP-R30-003. The decisive test was XTP's own: a re-test it paid for, under a tamper-seal protocol it wrote, on three randomly drawn vials, returned about 2mg of tirzepatide in a product sold as 30mg retatrutide. The next day XTP announced that no test had ever shown tirzepatide. This is a dated, source-linked account of what the certificates show.
-
CJC-1295 is the dirtiest peptide we test: 7.8% of vials fail purity (vs 0.14% for tirzepatide)
Across 683 third-party CJC-1295 assays in the TitrateLab corpus (as of July 2026), 7.76% test below 90% purity — roughly 57× the failure rate of tirzepatide and 33× retatrutide. This is a dated, certificate-linked breakdown of which batches failed, by how much, and when, with every vendor claim sitting beside its own certificate of analysis. No editorializing beyond what the certificates show.
-
The Peptide Vendor Graveyard: every verified shutdown, exit scam, and FDA action 2018-2026
A dated, cited archive of every major enforcement action, vendor shutdown, lab controversy, and regulatory milestone in the research peptide grey market from 2018 through April 2026. Primary sources only. Updated as events happen. This is the canonical reference for "what happened to that vendor" — so you stop relying on Reddit rumors and forum memory.
-
The July 23 PCAC review could collapse the peptide grey market's core demand. Here's what's at stake.
On July 23, 2026 the FDA's Pharmacy Compounding Advisory Committee meets to review whether BPC-157, TB-500, and ~12 other peptides should be restored to Category 1, a move HHS Secretary RFK Jr. announced on JRE #2461 back in February. If approved, compounding pharmacies could legally dispense these compounds for the first time since September 2023, and the grey-market moat that built Peptide Sciences, Amino Asylum, and the rest collapses. What the community needs to know before the vote.
-
HGH is discussed 16× more than it's tested. Here's what the 394 batches we have show.
HGH appeared in 6,172 peptide-tagged Discord messages across a 19-month window measured to April 2026. As of July 2026 our Certificate-of-Analysis database holds 394 full-length HGH assays, up from 70 when this was first published. That puts the discussion-to-testing gap at roughly 16 to 1 rather than 88 to 1 — still the widest of any compound we track, but far narrower than it was. Here's what the 394 batches show, and why HGH remains the hardest compound on this market to actually verify.
-
The peptide grey market collapsed in 9 months. Quality got dramatically better at the same time.
Between June 2025 and March 2026 the research-peptide grey market lost its three biggest players: Amino Asylum to an FDA raid, Science.bio to voluntary closure, and Peptide Sciences to a regulatory reversal. We measured what happened to quality across 62,079 published certificates from roughly 3,860 manufacturers, and the story nobody is telling is that purity went up while dose accuracy did not.
Reports and guides
-
The Molecule Is Clean. The Dose Is a Coin Flip.
A report on third-party certificate results, peptide purity and labeled-dose accuracy.
-
What the Grey Market Costs: Price Per Milligram
A price-per-milligram analysis of grey-market peptides, with methods and source limitations.
-
Lab Testing 101 for the Grey-Market Peptide Scene
What third-party certificate tests measure, what they cannot prove, and how to read the results.
Have a Certificate of Analysis we don't?
Drop it here. Anonymous by design — no account, no email, your IP is hashed weekly for abuse-prevention only. We OCR it, parse it, and add it to the corpus that powers every vendor page on this site. The long tail (Telegram-only sellers, niche OEMs) only gets covered if customers with skin in the game contribute one.
Browse by peptide
- Semaglutide 1011
- Tirzepatide 722
- Insulin 534
- Liraglutide 479
- Oxytocin 354
- Mgf 196
- LL-37 165
- Retatrutide 153
- THYMOSIN-ALPHA-1 147
- Mots-c 121
- BPC-157 115
- IGF-1 109
- GHRP-6 107
- SS-31 98
- MK-677 96
- Ghk-cu 94
- GHRP-2 92
- Sermorelin 89
- Orexin a 87
- Epitalon 83
- Melanotan-ii 80
- Cagrilintide 74
- Selank 74
- Semax 74
- PT-141 72
- P21 64
- Hgh 45
- Humanin 45
- Ipamorelin 45
- Dulaglutide 42
